Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.

Cephalalgia · 2022 · PMC8739573 · PMID 34521260

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

The LS mean change in acute medication use days showed a nominally significant difference from placebo starting at the first treatment period and persisting in the second and third treatment periods (Figure S3).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.